Amneal Pharmaceuticals, Inc. AMRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Affordable Medicines | $423.24M+2.1% | $436.65M-0.6% | $460.74M+7.8% | $433.43M+1.4% | $414.71M+6.0% | |
| AvKARE | $166.02M-3.7% | $210.74M+23.7% | $198.53M+24.5% | $163.04M-4.3% | $172.42M+6.0% | |
| Specialty | $133.27M+23.1% | —— | $125.24M+8.3% | $128.04M+23.1% | $108.3M+2.9% | |
| Other Operating Income by Business | ||||||
| Affordable Medicines | $6.94M+35.5% | $1K— | $117K— | $0— | $5.12M— | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $0— | —— | $0-100% | $0— | $0+100% | |
| Gross Profit by Business | ||||||
| Affordable Medicines | $190.79M+10.9% | $150.79M-15.3% | $180.28M+1.3% | $180.78M+8.6% | $172.08M+13.7% | |
| AvKARE | $39.08M+36.6% | $42.7M+81.9% | $42.26M+49.6% | $33.23M+29.7% | $28.6M+8.9% | |
| Specialty | $90.25M+63.4% | $103.7M+69.2% | $51.43M-18.7% | $72.25M+24.8% | $55.21M-8.6% | |
| Operating Income (Loss) by Business | ||||||
| Affordable Medicines | $120.94M+9.2% | $82M-10.8% | $85.63M-3.0% | $102.38M+1.1% | $110.79M+1,072% | |
| AvKARE | $22.4M+73.5% | $25.53M+242% | $27.03M+106% | $18.15M+65.3% | $12.91M+13.8% | |
| Specialty | $50.06M+234% | —— | $9.57M-70.5% | $35.49M+32.2% | $14.99M-48.7% | |
| SG&A by Business | ||||||
| Affordable Medicines | $41.32M+22.6% | $37.27M+9.9% | $37.17M+20.1% | $34.23M+8.2% | $33.72M+1.9% | |
| AvKARE | $16.68M+6.3% | $17.17M+7.2% | $15.23M+0.6% | $15.08M+3.0% | $15.69M+5.3% | |
| Specialty | $34.69M+12.0% | —— | $33.58M+21.1% | $30.31M+13.9% | $30.98M+22.9% | |
| Gain (Loss) from Litigation Settlement by Business | ||||||
| Affordable Medicines | -$694K— | —— | —— | $390K+156% | —— | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $0— | —— | $0— | $0— | —— | |
| Other by Business | ||||||
| Affordable Medicines | $6.14M-13.5% | $6.3M-7.6% | $7.74M-1.6% | $7.27M-18.4% | $7.1M+6.4% | |
| Specialty | $905K-27.5% | $555K-47.8% | $2.55M+612% | $1.23M+179% | $1.25M+70.7% | |
| Acquisition costs by Business | ||||||
| Affordable Medicines | $0— | —— | —— | —— | —— | |
| AvKARE | $0— | —— | —— | —— | —— | |
| Specialty | $0— | —— | —— | —— | —— | |
| Restructuring and other charges by Business | ||||||
| Affordable Medicines | $0— | $2.2M— | $90K+429% | $683K+1,189% | $0— | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $347K+167% | —— | $0— | $341K+337% | $130K-86.3% | |
| Currency translation by Business | ||||||
| Affordable Medicines | -$1.67M-2,838% | -$475K+46.5% | -$1.46M-599% | -$91K— | $61K— | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $0— | $0— | $0— | $0— | $0— | |
| Product development and studies by Business | ||||||
| Affordable Medicines | -$1M+37.5% | $7.25M— | -$1.3M-160% | -$900K-242% | -$1.6M-266% | |
| Specialty | $2.78M+19.8% | $1M+8.1% | $2.82M+8,403% | $2.37M+2,791% | $2.32M+436% | |
| Regulatory fees by Business | ||||||
| Affordable Medicines | $2.39M— | $1.15M-63.0% | $2.32M+49.5% | $2.93M+252% | $0— | |
| Specialty | $0— | $0— | $0— | $0— | $0— | |
| Cost of goods sold by Business | ||||||
| Affordable Medicines | $232.44M-4.2% | $285.86M+9.4% | $280.46M+12.5% | $252.65M-3.2% | $242.63M+1.1% | |
| AvKARE | $126.94M-11.7% | $168.04M+14.4% | $156.27M+19.1% | $129.81M-10.3% | $143.81M+5.4% | |
| Specialty | $43.02M-19.0% | —— | $73.81M+41.0% | $55.8M+20.9% | $53.08M+18.5% | |
| Materials and supplies by Business | ||||||
| Affordable Medicines | $8.82M+3.4% | $8.71M-44.6% | $6.23M-29.8% | $8.11M+34.6% | $8.53M-14.4% | |
| Specialty | $60K-70.4% | $986K+166% | $1.36M+884% | $450K+60.1% | $203K-52.9% | |
| R&D by Business | ||||||
| Affordable Medicines | $33.29M+7.4% | $28.01M-42.4% | $55.12M-3.5% | $41.9M+32.2% | $30.98M-9.9% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $5.1M-43.7% | —— | $8.23M+106% | $6.07M+39.4% | $9.06M+83.9% | |
| Goodwill by Business | ||||||
| Affordable Medicines | $158.02M-2.3% | $159.69M-1.2% | $160.17M-1.5% | $161.63M-0.7% | $161.72M-0.6% | |
| AvKARE | $69.47M0.0% | $69.47M0.0% | $69.47M0.0% | $69.47M0.0% | $69.47M-0.1% | |
| Specialty | $366.31M0.0% | $366.31M0.0% | $366.31M0.0% | $366.31M0.0% | $366.31M0.0% | |
| Employee compensation and benefits by Business | ||||||
| Affordable Medicines | $13.02M-3.8% | $12.24M+8.3% | $13.91M+24.4% | $14.69M+17.7% | $13.54M+16.8% | |
| Specialty | $11.94M+9.8% | $11.08M+25.1% | $10.97M+34.4% | $10.79M+19.2% | $10.87M+23.0% | |
| Facilities costs by Business | ||||||
| Affordable Medicines | $1.49M-8.8% | $1.65M-4.6% | $1.76M+9.8% | $1.79M+5.9% | $1.63M-3.4% | |
| Specialty | $35K-95.3% | $63K-95.8% | $409K-74.4% | $735K-50.9% | $750K-39.9% | |
| Milestones by Business | ||||||
| Affordable Medicines | $500K+100% | —— | $22.5M-5.7% | $6.35M+464% | $250K-92.9% | |
| Specialty | $0-100% | $3M— | $0— | $0— | $3M— | |
| Intellectual property legal development expenses by Business | ||||||
| Affordable Medicines | $1.49M-12.8% | $1.32M-30.8% | $2.38M+33.1% | $1.98M+91.7% | $1.71M+78.4% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $49K-9.3% | $91K— | $59K-67.4% | $39K+290% | $54K+125% | |
| Net revenue by Product | ||||||
| Auto-Injector | $41.91M-13.0% | $39.1M+3.1% | $78.94M+11.7% | $66.59M+14.3% | $48.16M+13.0% | |
| Biosimilar | $22.3M-21.9% | $29.43M-23.7% | $17.01M-44.6% | $25.25M-14.4% | $28.54M+6.9% | |
| Central nervous system | $83.38M+23.3% | $104.75M+36.8% | $77.63M+5.8% | $83.43M+30.5% | $67.61M+2.0% | |
| Distribution | $89.15M-15.0% | $107.68M+1.1% | $96.22M-5.3% | $99.66M-14.2% | $104.9M-4.4% | |
| Government label | $59.95M+19.6% | $86.79M+85.2% | $87.76M+109% | $45.42M+25.4% | $50.14M+43.5% | |
| Hormonal / allergy | $35.93M+5.1% | $47.63M+28.7% | $37.69M+16.7% | $35.42M+11.5% | $34.2M+16.4% | |
| Injectable | $49.94M+43.5% | $37.44M-21.9% | $54.37M+25.9% | $34.65M-11.3% | $34.79M-1.2% | |
| Institutional | $9.82M-10.8% | $8.38M-21.9% | $5.85M-37.7% | $10.13M-13.9% | $11.01M+1.4% | |
| International | $5.32M+331% | $2.7M+109% | $6.29M+39.5% | $1.9M+32.9% | $1.23M-28.3% | |
| Oral liquid | $12.09M-48.6% | $14.98M-39.7% | $16.42M-27.2% | $17.88M-25.8% | $23.55M-26.2% | |
| Oral solid | $171.1M-4.4% | $188.71M+3.1% | $180.46M+11.9% | $178.26M+1.3% | $178.95M+5.7% | |
| Other dosage forms | $46.61M-17.4% | $68.15M+15.6% | $59.66M+17.8% | $68.19M+38.3% | $56.42M+30.4% | |
| Other therapeutic classes | $13.95M+115% | $14.55M+101% | $9.92M+25.5% | $8.7M+4.1% | $6.49M+27.1% | |
| Subtotal dosage forms | $417.92M+1.1% | $433.95M-0.9% | $454.45M+7.5% | $431.52M+1.3% | $413.47M+6.1% | |
| Subtotal therapeutic classes | $133.27M+23.1% | $166.93M+38.1% | $125.24M+10.3% | $127.54M+22.6% | $108.3M+7.5% | |
| Transdermal | $73.96M+71.8% | $56.14M+19.9% | $47.6M+8.4% | $40.71M-18.1% | $43.06M+6.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
